Aurobindo Pharma Ltd SHARE PRICE [LIVE]

BSE: 524804
To view real time prices Login to your account
Already an existing customer? - Login Now!
BSE Click here to view BSE data
Live Chart
Loading, Please wait...
Error in Fetching Data, Please retry later.
No data available.
MKT Cap:
52-wk High:
52-wk Low:
Prev close:
Div yield:

Fundamental analysis


0 250 500 750 1 000
Financial trend

What is not working for the company?

What is working for the company?

Underperformed both Sector by -18.54% and Sensex by -31.75%
MARKET CAP (Large Cap Stock)Rs 27,612 Cr
PE (TTM) 12.72
PE Ratio12.72
Price to Book Value1.07
EV to EBIT10.17
EV to EBITDA6.96
EV to Capital Employed1.08
EV to Sales1.05
PEG Ratio0.00
Dividend Yield1.60%
ROCE (Latest)10.98%
ROE (Latest)8.89%
NameDec 22Sep 22
Promoters (Change:-0.00) 51.83%51.83%
FIIs (Change:0.91) 22.31%21.4%
Mutual Funds (Change:-1.46) 7.5%8.96%
Insurance Companies (Change:-0.11) 7.15%7.26%
Other DIIs (Change:-0.10) 0.25%0.35%
Non Institution (Change:0.76) 10.96%10.2%

Similar Stocks

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made LUMPSUM investment of ₹ 1,00,000

in Aurobindo Pharma Ltd

Months ago

My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %


Frequently Asked Questions

What is the Share price of AUROBINDO PHARMA LTD. (AUROPHARMA)?

AUROBINDO PHARMA LTD. (AUROPHARMA) share price as of March 22, 2023, on NSE is Rs 478.75 (NSE) and Rs 479.10 (BSE) on BSE.


Yes, You can buy AUROBINDO PHARMA LTD. (AUROPHARMA) shares by opening a Demat account with Angel One.


AUROBINDO PHARMA LTD. (AUROPHARMA) share can be brought through the following modes:
  1. Direct investment: You can buy AUROBINDO PHARMA LTD. (AUROPHARMA) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to AUROBINDO PHARMA LTD. (AUROPHARMA) shares.

In which sector do AUROBINDO PHARMA LTD. (AUROPHARMA) belong?


Is Aurobindo Pharma a Debt free Company?

No, Aurobindo Pharma is not a debt free company.

What is the main business of Aurobindo Pharma?

The main business of Aurobindo Pharma is to manufacture semi-synthetic penicillin (SSP) through over 27 manufacturing and packaging facilities situated globally. It also has a presence in several therapeutic segments, including neurosciences, gastroenterology, cardiovascular, anti-diabetics, anti-retrovirals, and anti-biotics

Who are the promoters of Aurobindo Pharma?

Some of the promoters of Aurobindo Pharma include Rpr Sons Advisors Private Limited, Mrs.P.Suneela Rani (Jointly Holding), K Nityananda Reddy, Kirthi Reddy Kambam, Venkata Ramprasad Reddy Penaka, and Axis Clinicals Limited, Trident Chemphar Limited, Rpr Sons Advisors Pvt.Ltd (Jointly Holding).

What are the Subsidiaries that comes under Aurobindo Pharma?

Some of the subsidiaries that come under Aurobindo Pharma are APL Pharma Thai Limited, All Pharma (Shanghai) Trading Company Limited, Aurobindo Pharma USA Inc., Aurobindo Pharma Industria Farmaceutica Ltda, Brazil, Helix Healthcare B.V., The Netherlands, Auro Pharma Inc., Canada, and APL Healthcare Limited.


Today's live share price for Aurobindo Pharma Ltd is NSE: ₹ 478.75, BSE: ₹ 479.10 with a current market capitalization of .

Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in 26th December of the year 1986 as a private limited company. Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it. APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations. The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products. APL is running with 14 manufacturing plants across the world conforming to GMP / ISO regulations and an extremely well equipped R&D facility. Aurobindo Pharma has identified international operations also, catering to over 100 countries. The Company has accelerated the DMF/ANDA filings programme in its efforts to build a broad product portfolio for the regulated markets. Cumulatively, the Company has filed a total of 337 DMFs (Drug Master Files), of which 110 are with US FDA, and 133 in Europe including with the EDQM and 102 in other countries. This is one of the highest filings. The Company commenced its operations during the year 1988-89 with a single unit manufacturing semi synthetic penicillins (SSPs) at Pondicherry and it became a public venture in 1992. In the same year 1992, another unit was also set up for the manufacture of CMIC Chloride, a bulk drug intermediate at Pashamylaram, near Hyderabad through another company, namely Chaitanya Organics Pvt. Ltd., later in 1994-95 it was merged with the company. The commercial production of the pharmaceutical formulation unit was started in April of the year 1994. Aurobindo Pharma had gone public in 1995 by listing its shares in various stock exchanges in the country. Glaxo (India), the Indian subsidiary of the UK-based multinational came to an alliance with the company to meet its global bulk drug requirements during the year 1997. In the year 1998, the company had launched new formulations like auronim Suspension in the paediatric segment. During 1999-2000, the company has diversified its product portfolio further with the introduction of wide range of Cephalosporins (Oral & Sterile) and anti - virals in addition to macrolides, anti-ulcerants, quinolones, semi-synthetic penicillins and formulations for domestic and export market. APL made Joint Ventures for formulations business in US, with an investment of a million in the year 2000. Sri Chakra Remedies Ltd was amalgamated with the company in the identical year of 2000. The Company has launched an exclusive anti-viral division Immune during the year 2001 to educate and to provide preventive drug care for HIV/AIDS patients in the country. APL had launched two more drugs in the same year of 2001, namely Efavirenz (Viranz) and Nelfinavir (NELVEX) for the treatment of AIDS. During the year 2001-02 the company acquired 79% stake in Ranit Pharma Company under the same management. Ranit Pharma and Calc Private Ltd were amalgamated with APL as at 1st April of the year 2002. Citadel Aurobindo Biotech Ltd, a 50:50 Joint Venture (JV) Company introduced Aztreonam a Monabactam Betalactam antibiotic for the first time in the Indian Pharma Market with a brand name 'TREONAM' in the year 2003. During the same year the JV was happened between APL and Shanxi Tongling Pharmaceuticals Company, as an upshot formulated the JV Company under the name of Aurobindo Tongling (Datong) pharmaceuticals Ltd, China, for manufacture of pharmaceutical products to the local market. APL's 100% subsidiary company in China had commenced its commercial production during the year 2003-2004, which was formulated to procure raw material 6 APA at an economical cost. APL also launched the second JV Company in US for the purpose of Research and Development. During the year 2004, the company received its first Certificate of Suitability (CoS) approval from the European Directorate for Quality Medicines (EDQM) for its product in the therapeutic segment of gastroenterology. During the year 2004-05 the company had acquired a sterile plant of Dee Pharma for the consideration of Rs.38 million which located at Bhiwadi in Rajasthan. US FDA part of Department of health and human science approved the Unit VIII facility of the company in the year of 2005 as a site to manufacture of APIs for the US Market. Also in the same year APL had received US FDA clearance for AIDS drug. The State Labour Department of the Government of Andhra Pradesh has awarded the 'Best Management Award' for the year 2005 for the Company's contributions towards community development, harmonious employee relations and their welfare. During the year 2005-06, the company made a strategic entry with its generic formulations in the premium markets of USA & Europe, participated in the PEPFAR program initiated by the Government of USA and consolidated its strengths in the less regulated and emerging markets. Also in same year APL had acquired the UK based Milpharm Limited, the generic formulation pharmaceutical company engaged in marketing generic formulations mainly in the UK market. During March of the year 2007, the US FDA has granted final approval for the Company's Didanosine Oral Suspension (Pediatric Powder) 10 mg / ml. As at June 13th of the year 2007 the Company unveiled their new Logo and Corporate Identity at a ceremony in Hyderabad. The new corporate logo reflects this pace and leadership. Artistic lines intersect to make up the company's initials 'A' and 'P'. The way the initials 'A' and 'P' have joined conveys the spirit of 'partnership' with the company's business. The Hon'ble High Court of Andhra Pradesh has approved the scheme of arrangement for merger of APL Life Sciences and Senor Organics into the company and the utilisation of share premium account of the company during June of the year 2007. APL concluded a strategic deal, for acquisition of intellectual property & marketing suthorizations, with TAD Italy, a generic company registered in Italy during March of the year 2008. This acquisition will give Aurobindo an access to more than 70 ready to market products, which will fast track Aurobindo's entry into the Italian generic market. As a part of this deal, APL also acquired high profile OTC brands - Mapooro and Carmiooro from TAD in same period of the year 2008. The Company is increasing its presence in PEPFAR programme and hopes to consolidate its position further.

Read more

Enjoy Zero Brokerage on Equity Delivery

Join our 1 Cr+ happy customers